Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 12, 2016, Pages 1581-1583

  Filippatos, T D ^a   Tsimihodimos, V ^a   Elisaf, M S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

arterial hypertension; blood pressure; body weight; Sodium glucose co transporter 2 inhibitors; uric acid

Indexed keywords

LOOP DIURETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; URIC ACID;

ADRENERGIC SYSTEM; ARTERIAL STIFFNESS; BLOOD PRESSURE; CARDIAC PATIENT; DIABETIC PATIENT; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; HEART HEMODYNAMICS; HEART RATE; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; OXIDATIVE STRESS; PLASMA VOLUME; VASCULAR RESISTANCE; WEIGHT REDUCTION;

EID: 84976292796     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2016.1201073     Document Type: Editorial

References (20)

1. I.Tikkanen, K.Narko, C.Zeller, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420–428.•• A study that showed the blood pressure-lowering effects of empagliflozin.
2. R.Chilton, I.Tikkanen, C.P.Cannon, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17:1180–1193.
3. B.Zinman, C.Wanner, J.M.Lachin, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
4. W.L.Baker, L.R.Smyth, D.M.Riche, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8:262–275.e9.•• A meta-analysis which showed that blood pressure reduction is a class-effect of SGLT2 inhibitors.
5. A.Liakos, T.Karagiannis, E.Athanasiadou, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:984–993.
6. H.J.Lambers Heerspink, D.De Zeeuw, L.Wie, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853–862.
7. G.Kimura Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis. J Am Soc Hypertens. 2016;10:271–278.
8. K.Tamura, H.Wakui, K.Azushima, et al. Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of type 2 diabetes. Hypertens Res. 2016;39:396–398.
9. M.R.Weir, I.Kline, J.Xie, et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014;30:1759–1768.• A study that showed the potassium-sparing effects of SGLT2 inhibitors.
10. M.A.Weber, T.A.Mansfield, V.A.Cain, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4:211–220.
11. M.H.Muskiet, E.J.van Bommel, D.H.van Raalte. Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes. Lancet Diabetes Endocrinol. 2016;4:188–189.
12. J.E.Neter, B.E.Stam, F.J.Kok, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertens. 2003;42:878–884.
13. W.T.Cefalu, K.Stenlof, L.A.Leiter, et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58:1183–1187.
14. M.H.Muskiet, L.Tonneijck, M.M.Smits, et al. Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. Lancet Diabetes Endocrinol. 2015;3:367–381.
15. Y.Chino, Y.Samukawa, S.Sakai, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35:391–404.
16. D.I.Feig, B.Soletsky, R.J.Johnson. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300:924–932.
17. J.Jordan, J.Tank, K.Heusser, et al. Empagliflozin (EMPA) has no discernable effect on muscle sympathetic nerve activity (MSNA) in patients with type 2 diabetes (T2DM) despite reductions in blood pressure (BP) and weight. Diabetes. 2014;63(suppl. 1):A265(abstract).
18. D.Z.Cherney, B.A.Perkins, N.Soleymanlou, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28.
19. H.J.Heerspink, E.Johnsson, I.Gause-Nilsson, et al. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab. 2016;18:590–597.
20. T.D.Filippatos, E.N.Liberopoulos, M.S.Elisaf. Dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2015;6:29–41.